GTC
PTCT icon

Ghost Tree Capital’s PTC Therapeutics PTCT Stock Holding History

Ghost Tree Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100,000
Closed -$2M – 64
2017
Q3 		$2M Buy
+100,000
New +$1.96M 0.42% 54
2015
Q4 		– Sell
-75,000
Closed -$2M – 67
2015
Q3 		$2M Buy
+75,000
New +$3.21M 0.9% 45

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ghost Tree Capital's PTCT Position: Q3 2024 in Review

Ghost Tree Capital sold out of PTC Therapeutics (PTCT) in Q3 2024, closing a stake of 19,000 shares — an estimated $581K sold.

Ghost Tree Capital first reported a position in PTCT in Q3 2014 and held it in 12 quarters. The position peaked at $23.5M in Q3 2018. 202 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

  • Ghost Tree Capital reported no remaining PTC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 19,000 PTC Therapeutics shares in Q3 2024, an estimated $581K.
  • Ghost Tree Capital first reported a position in PTC Therapeutics in Q3 2014 and held it in 12 quarters.
  • Ghost Tree Capital's PTC Therapeutics position peaked at $23.5M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.